The Lynx Group

Web Exclusives

Web Exclusives — September 6, 2019
AVBCC is delighted to announce that John O’Brien, PharmD, MPH, former Senior Advisor to the Secretary, US Department of Health & Human Services (HHS), will present a Summit Keynote speech and Q&A at the 2019 AVBCC Summit on Thursday, October 17, in New York City.
Read Article


Web Exclusives — July 26, 2019
AVBCC is delighted to announce that Scott Gottlieb, MD, former US Food and Drug Administration Commissioner, will be the keynote speaker at the 2019 AVBCC Summit on Thursday, October 17, in New York City. He will share insights he has gained over his long career at the forefront of healthcare change with the AVBCC Summit attendees.
Read Article

Web Exclusives — July 9, 2019
On February 26, 2018, the FDA approved a new indication for abemaciclib (Verzenio; Eli Lilly), a CDK4/CDK6 inhibitor, alone or in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.
Read Article

Web Exclusives — June 26, 2019
Lung cancer is the second most frequently diagnosed malignancy in both men and women (following prostate and breast cancer, respectively), and the leading cause of cancer deaths overall. Non–small-cell lung cancer (NSCLC) is the most common type, with the more aggressive small-cell lung cancer (SCLC) making up approximately 10% to 15% of cases.
Read Article

Web Exclusives — June 12, 2019
On June 10, 2019, the US Food and Drug Administration (FDA) granted accelerated approval to the novel antibody-drug conjugate polatuzumab vedotin-piiq (Polivy; Genentech) in combination with bendamustine plus rituximab for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least 2 previous therapies. This is the first chemoimmunotherapy regimen approved for use in patients with DLBCL who are ineligible for hematopoietic stem-cell transplantation.
Read Article

Web Exclusives — May 14, 2019
On May 3, 2019, the US Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla; Genentech) for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Patients should be selected for treatment with this agent based on an FDA-approved companion diagnostic test (Ventana Medical System’s PATHWAY anti-HER-2/neu [4B5] Rabbit Monoclonal Primary Antibody assay or INFORM HER2 Dual ISH DNA Probe Cocktail assay).
Read Article

Web Exclusives — May 7, 2019
On May 2, 2019, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo; Agios Pharmaceuticals, Inc) for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved companion diagnostic test, in patients who are aged ≥75 years or who have comorbidities that preclude the use of intensive induction chemotherapy.
Read Article


Web Exclusives — April 16, 2019
  • Keytruda Receives Expanded Indication for First-Line Treatment of Non–Small-Cell Lung Cancer
  • FDA Changes Recommended Contraception Period Following Soltamox Therapy
Read Article

Page 3 of 7

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: